A licensing agreement for Zeneo Hydrocortisone in the US and Canada
A licensing agreement for Zeneo Hydrocortisone in the US and CanadaLATEST
Zeneo Hydrocortisone to be licensed in the US and Canada
The news confirms the pharmaceutical firms’ interest in Crossject’s product
The remuneration of the contract looks fine, in our view
We expect more agreements to come
FACT
Crossject has just announced it has signed a licensing agreement with Eton Pharmaceuticals for the marketing of Zeneo Hydrocortisone in the US and Canada.
ANALYSIS
Eton Pharmaceuticals is a speciality pharmaceutical company focused on developing and commercialising innovative treatments for rare paediatric diseases. Adrenal crisis, the indication for hydrocortisone, is a potentially life-threatening rare medical condition requiring immediate emergency treatment (patients with adrenal insufficiency can go into adrenal crisis if their cortisol levels are too low). Under this agreement, Eton will be responsible for all regulatory and commercial activities, including licensing, regulatory filing fees, distribution, and promotion. Crossject will receive milestones of US$5m until the product reaches the market (US$0.5m upon signing, US$0.5m escrowed and the rest over three years). Once the product is marketed, Crossject will receive a “mid-double-digit” price for each Zeneo Cortisone sold, a 10% royalty on net sales and sales milestones of US$6m subject to three thresholds in Eton’s annual sales. In the US, Eton estimates that 100,000 people currently suffer from adrenocortical insufficiency and are at risk of adrenal crisis. Note we had expected sales of Zeneo Hydrocortisone to reach c. €22m in…2028 with a 50% probability of success, so we feel rather comfortable with the numbers mentioned (which again concern the US and Canada only) while the market launch will, however, come later than we had initially expected (no earlier than FY23 at best in our view vs FY22 in our numbers). The other positive piece of news of this release is that yet another pharmaceutical company after Desitin in Germany for Zeneo Midazolam seems to believe firmly in the group’s device. The remuneration of Crossject seems also OK with a decent unit price according to the group’s hint and a rather nice 10% in royalties on net sales once Zeneo Hydrocortisone reaches the market.
IMPACT
The share price has reacted very positively to this piece of news, the latter confirming our positive stance on the stock. We will not amend our numbers at this stage, but will update all our assumptions (i.e. on all product launches planned, both in terms of quantities and prices) within the next few days.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.